Skip Navigation

Dr. Hui Mao granted RO1 from National Cancer Institute

08/01/2011

Dr. Hui Mao’s laboratory has recently received a 5-year R01 grant from National Cancer Institute (NCI) to develop novel magnetic nanoparticles and MRI methods for image-guided drug delivery and treatment monitoring for improving the treatment of pancreatic cancer.  In this newly funded project, titled “MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer”, Dr. Mao’s lab at CSI will continue to collaborate with Dr. Lily Yang, Associate Professor of Surgery at Department of Surgery and Winship Cancer Institute.  This is the second major grant received by Drs. Mao and Yang’s laboratories which participate in the NCI Alliance for Nanotechnology in Cancer with a Cancer Nanotechnology Platform Partnerships (CNPP) U01 grant last year. 

Systemic chemotherapy is a common approach to the chronic management of many cancers, including pancreatic cancer which is one of the most lethal malignancies and difficult to treat. However, the efficacy of current chemotherapy is limited by poor efficiency in delivery of the therapeutic agent to the tumor and systemic toxicity. In this project, this research team will use their latest discoveries in biomarker targeting, biocompatible polymers and novel MRI techniques for tracking magnetic nanoparticles to develop a “stealth”, multi-functional magnetic nanoparticle platform for imaging-guided drug delivery.  By combining capabilities of magnetic resonance imaging, receptor specific tumor targeting and optimized drug loading and release and high sensitivity and contrast MRI methods, the success of this project may lead to a new MRI guided and monitored systemic delivery of chemotherapy drugs for the treatment of pancreatic cancer followed by molecular imaging based MRI evaluation of treatment responses.  

Other investigators of this project include: Dr. Kevin H. Kim, MD of Department of Radiology and Imaging Sciences, Dr. Liya Wang, MD of CSI and Department of Radiology and Imaging Sciences and Dr. Volkan Adsay, MD from Department of Pathology.

More details about this newly funded research project.

More details about Drs. Mao and Yang's research in cancer nanomedicine.